FibroBiologics Inc Dossier - Source-backed chat

FibroBiologics Inc

FBLGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.61

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.21Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $8.4M

Enterprise Value $9.4M

Shares Outstanding 7M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

FibroBiologics, Inc. (NASDAQ: FBLG) is a pioneer in fibroblast-based cell therapies, representing a novel therapeutic modality that potentially outperforms traditional mesenchymal stem cells (MSCs) in regeneration and immune modulation. The company's investment thesis centers on its deep intellectual property moat (over 270 patents issued and pending) and its transition into a clinical-stage execution phase. With the first patients dosed in its Australian Phase 1/2 trial for CYWC628 in diabetic foot ulcers (DFUs) and upcoming IND milestones for psoriasis (CYPS317) and multiple sclerosis (CYMS101), FBLG offers high-upside optionality. However, as a pre-revenue biotech with a tight cash position ($1.5 million as of March 31, 2026), near-term performance is highly dependent on clinical execution, regulatory approvals, and dilutive or non-dilutive financing.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$13.50

High · most bullish analyst$19.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

CYWC628 clinical trials experience severe enrollment delays or fail to show statistically significant efficacy compared to standard of care. The FDA issues clinical holds or requests extensive additional preclinical data for the CYPS317 and CYMS101 IND submissions. Capital reserves deplete rapidly, forcing highly dilutive equity raises at depressed stock prices or risking Nasdaq delisting.

Base CaseCentral scenario

The Australian Phase 1/2 trial for CYWC628 in diabetic foot ulcers successfully completes enrollment of 120 patients, with positive interim data in Q3 2026 and clean safety/efficacy topline results by the end of 2026. The FDA clears the IND for CYPS317 in psoriasis, allowing clinical trial initiation. The company secures additional capital through its existing ATM facility or strategic partnerships, mitigating immediate going-concern risks.

Bull CaseUpside scenario

Successful clinical readouts of CYWC628 in diabetic foot ulcers (DFU) and IND clearances for psoriasis (CYPS317) and multiple sclerosis (CYMS101) validate the therapeutic efficacy of the fibroblast platform, paving the way for lucrative out-licensing partnerships and substantial valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage in fibroblast-based cell therapies, which are easier to source, culture, and differentiate than traditional stem cells.
Extensive intellectual property portfolio with over 270 issued and pending patents globally, creating a highly defensible competitive moat.
Active clinical execution with the first patients already dosed in the Phase 1/2 diabetic foot ulcer trial in Australia.
Broad pipeline optionality targeting high-value chronic indications including wound healing, psoriasis, multiple sclerosis, and degenerative disc disease.

Key Investment Risks

High cash burn rate relative to limited cash reserves ($1.5 million as of March 31, 2026), presenting significant near-term dilution or going-concern risk.
Binary clinical trial risk, where negative or mediocre data from the CYWC628 Australian trial would severely impair the company's valuation.
Regulatory hurdles, including potential delays in FDA IND clearances for CYPS317 and CYMS101.
Nasdaq listing compliance vulnerability due to historical stock price volatility and low market capitalization.

Thesis Invalidation Triggers

Failure of CYWC628 to meet primary safety or efficacy endpoints in the Phase 1/2 Australian trial.
Inability to secure additional dilutive or non-dilutive funding before cash reserves are fully exhausted.
A definitive clinical hold or rejection by the FDA regarding the IND applications for psoriasis or multiple sclerosis.
Delisting from the Nasdaq Capital Market due to failure to maintain minimum bid price or public float requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.